Enhancing proteasome‐inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2017.11.045
Abstract: Abstract The establishment of more effective treatments that can circumvent chemoresistance in Multiple Myeloma (MM) is a priority. Although bortezomib (BTZ) is one of the most potent proteasome inhibitors available, still possesses limitations related to… read more here.
Keywords: cd38; multiple myeloma; proteasome inhibitory; cd38 targeted ... See more keywords